REFERENCES
1. Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging. 2019;36:1015-26.
2. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442-58.
3. Buttgereit F, Matteson EL, Dejaco C. Polymyalgia rheumatica and giant cell arteritis. JAMA. 2020;324:993-4.
4. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2009;61:1454-61.
5. Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res. 2017;69:1282-5.
7. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheumatol. 2011;63:633-9.
8. Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23:82.
9. Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170-6.
10. Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology. 2012;51:730-4.
11. Aschwanden M, Kesten F, Stern M, et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis. 2010;69:1356-9.
12. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheumatol. 2006;55:131-7.
13. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology. 2017;56:506-15.
14. Salvarani C, Padoan R, Iorio L, et al. Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun Rev. ;2023:103415.
15. Hemmig AK, Gozzoli D, Werlen L, et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. Semin Arthritis Rheumatol. 2022;55:152017.
16. Burg LC, Karakostas P, Behning C, Brossart P, Kermani TA, Schäfer VS. Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica - a prospective cohort study. Ther Adv Musculoskelet Dis. 2023;15:1759720X221149963.
17. De Miguel E, Macchioni P, Conticini E, et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology. 2024;63:158-64.
18. Tomelleri A, van der Geest KSM, Khurshid MA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat Rev Rheumatol. 2023;19:446-59.
19. Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74:1808-17.
20. Berger CT, Sommer G, Aschwanden M, Staub D, Rottenburger C, Daikeler T. The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. Swiss Med Wkly. 2018;148:w14661.
21. Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4:e000612.
22. Rottenburger C, Mensch N, Imfeld S, et al. 18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches. Swiss Med Wkly. 2021;151:w20512.
23. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234-45.
24. Ceccato F, Roverano SG, Papasidero S, Barrionuevo A, Rillo OL, Paira SO. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol. 2006;12:167-71.
25. Cimmino MA, Camellino D, Paparo F, et al. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. Rheumatology. 2013;52:1865-72.
26. Owen CE, Poon AMT, Lee ST, et al. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology. 2018;57:345-53.
27. Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology. 2009;48:123-7.
28. Menéndez J, Campoamor Serrano MT, Nuño Mateo FJ, Morís De La Tassa J. [Distal musculo-skeletal manifestations in rheumatic polymyalgia]. Rev Clin Esp. 2002;202:385-7.
29. Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. Arthritis Rheumatol. 1996;39:73-80.
30. Karmacharya P, Donato A, Aryal M, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol 2016;34:404-15. Available from: https://api.semanticscholar.org/CorpusID:32480252 [Last accessed on 12 Mar 2024].
32. Paltta J, Suuronen S, Pirilä L, Palomäki A. Differential diagnostics of polymyalgia rheumatica in a university hospital in Finland. Scand J Rheumatol. 2023;52:689-95.
33. Mahmood SB, Nelson E, Padniewski J, Nasr R. Polymyalgia rheumatica: an updated review. Cleve Clin J Med. 2020;87:549-56.
34. Donskov AO, Mackie SL, Hauge EM, et al. An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists. Rheumatology. 2023;62:2797-805.
35. Gärtner M, Fabrizii JP, Koban E, et al. Immediate access rheumatology clinic: efficiency and outcomes. Ann Rheum Dis. 2012;71:363-8.
36. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology. 2016;55:66-70.
37. Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med. 2020;7:589794.
38. Patil P, Williams M, Maw WW, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33:103-6.
39. Monti S, Delvino P, Montecucco C. A new era for the early and non-invasive diagnosis of giant cell arteritis: the use of fast-track ultrasound in clinical practice. Appl Sci. 2022;12:1621.
40. Frølund LL, Våben C, Dam M, et al. Fast track clinic for early diagnosis of polymyalgia rheumatica: Impact on symptom duration and prednisolone initiation. Joint Bone Spine. 2021;88:105185.
41. Chrysidis S, Lage-Hansen PR, Svendsen N, Diamantopoulos AP. The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients. BMC Rheumatol. 2021;5:37.
42. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2012;64:943-54.
43. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheumatol. 2005;53:33-8.
44. Marsman DE, den Broeder N, Boers N, et al. Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica. Clin Exp Rheumatol. 2021;39:32-7.
45. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheumatol. 2000;30:17-24.
46. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheumatol. 2020;50:521-5.
47. Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022;81:838-44.
48. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053-62.
49. Dasgupta B, Unizony S, Warrington KJ, et al. LB0006 SARILUMAB in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR). Ann Rheum Dis. 2022;81:210.1-1.
50. Devauchelle-Pensec V, Saraux L, Berthelot JM, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology. 2018;57:666-70.
51. van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology. 2015;54:1397-402.
52. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheumatol. 1993;36:1286-94.
53. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456-8.
55. van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66:1927-38.
56. Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40-7.
57. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906-15.
58. Brun JG, Madland TM, Gran JT, Myklebust G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol. 2005;34:125-8.
59. Michailidou D, Johansson L, Kuley R, et al. Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica. Rheumatology. 2023;62:2880-6.
60. Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72:47-56.
61. Michailidou D, Duvvuri B, Kuley R, et al. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Res Ther. 2022;24:160.
62. Kuley R, Stultz RD, Duvvuri B, et al. N-formyl methionine peptide-mediated neutrophil activation in systemic sclerosis. Front Immunol. 2021;12:785275.
63. Pulsatelli L, Boiardi L, Pignotti E, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheumatol. 2008;59:1147-54.
64. McCarthy EM, MacMullan PA, Al-Mudhaffer S, et al. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study. J Rheumatol. 2014;41:931-7.
65. Owen CE, McMaster C, Liew DFL, Leung JL, Scott AM, Buchanan RRC. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. Int J Rheum Dis. 2021;24:56-62.
66. Conticini E, Falsetti P, d’Alessandro M, et al. Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study : Polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound. Intern Emerg Med. 2023;18:1929-39.
67. Hattori K, Hirano Y, Kojima T. Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis. 2020;23:1581-6.
68. Fukui S, Nunokawa T, Kobayashi S, et al. MMP-3 can distinguish isolated PMR from PMR with GCA: a retrospective study regarding PMR and GCA in Japan. Mod Rheumatol. 2016;26:259-64.
69. van Sleen Y, Therkildsen P, Nielsen BD, et al. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. Arthritis Res Ther. 2022;24:65.
70. van Sleen Y, Boots AMH, Abdulahad WH, et al. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology. 2020;59:176-84.
71. Cowley S, Kirby C, Harkins P, et al. POS0716 differences in clinical and ultrasound characteristics of polymyalgia rheumatica patients with subclinical giant cell arteritis compared to those with clinical giant cell arteritis. Ann Rheum Dis. 2023;82:645.
72. Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open. 2015;1:e000100.
73. Ruta S, Rosa J, Navarta DA, et al. Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis. Clin Rheumatol. 2012;31:1383-7.
74. Iagnocco A, Finucci A, Ceccarelli F, Scirocco C, Rutigliano IM. Musculoskeletal ultrasound in the evaluation of polymyalgia rheumatica. Med Ultrason. 2015;17:361-6.
75. Ottaviani S, Goossens J, Demaria L, Forien M, Palazzo E, Dieudé P. Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica. Clin Exp Rheumatol. 2020;38:1170-5.
76. Suzuki T, Yoshida R, Hidaka Y, Seri Y. Proliferative synovitis of the shoulder bursae is a key feature for discriminating elderly onset rheumatoid arthritis mimicking polymyalgia rheumatica from polymyalgia rheumatica. Clin Med Insights Arthritis Musculoskelet Disord. 2017;10:1179544117745851.
77. Nawata M, Someya K, Kosaka S, et al. Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset. Mod Rheumatol. 2023;33:318-22.
78. Bosch P, Bond M, Dejaco C, et al. Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. RMD Open. 2023;9:e003379.
79. Chrysidis S, Duftner C, Dejaco C, et al. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT large vessel vasculitis ultrasound working group. RMD Open. 2018;4:e000598.
80. Camellino D, Duftner C, Dejaco C. New insights into the role of imaging in polymyalgia rheumatica. Rheumatology. 2021;60:1016-33.
81. Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758-61.
82. Salvarani C, Barozzi L, Boiardi L, et al. Lumbar interspinous bursitis in active polymyalgia rheumatica. Clin Exp Rheumatol. 2013;31:526-31.
83. Kobayashi K, Nakagomi D, Kobayashi Y, et al. Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for polymyalgia rheumatica. Rheumatology. 2022;61:1185-94.
84. Huwart A, Garrigues F, Jousse-Joulin S, et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther. 2018;20:11.
85. Mcgonagle D, Pease C, Marzo-Ortega H, O’Connor P, Gibbon W, Emery P. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol. 2001;28:1837-41.
86. Marzo-Ortega H, Rhodes LA, Tan AL, et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis Rheumatol. 2007;56:3496-501.
87. Fruth M, Buehring B, Baraliakos X, Braun J. Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica. Clin Exp Rheumatol. 2018;36:86-95.
88. Fruth M, Seggewiss A, Kozik J, Martin-Seidel P, Baraliakos X, Braun J. Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica. Rheumatology. 2020;59:2864-71.
89. Laporte JP, Garrigues F, Huwart A, et al. Localized myofascial inflammation revealed by magnetic resonance imaging in recent-onset polymyalgia rheumatica and effect of tocilizumab therapy. J Rheumatol. 2019;46:1619-26.
90. Wakura D, Kotani T, Takeuchi T, et al. Differentiation between polymyalgia rheumatica (PMR) and elderly-onset rheumatoid arthritis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: is enthesitis a new pathological lesion in PMR? PLoS One. 2016;11:e0158509.
91. Rehak Z, Sprlakova-Pukova A, Bortlicek Z, et al. PET/CT imaging in polymyalgia rheumatica: praepubic (18)F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis. Radiol Oncol. 2017;51:8-14.
92. Camellino D, Dejaco C. Should 18F-FDG-PET imaging be used in the diagnosis of GCA? Nat Rev Rheumatol. 2019;15:388-90.
93. van der Geest KSM, van Sleen Y, Nienhuis P, et al. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. Rheumatology. 2022;61:1072-82.
94. Brinth LS, Hansen A, Jensen DV, Madsen OR, Broholm R, Krakauer M. Diagnostic value of composite and simplified FDG-PET/CT scores in polymyalgia rheumatica and the influence of recent glucocorticoid treatment-a retrospective diagnostic cohort study. Diagnostics. 2023;13:514.
95. Yates M, Watts RA, Swords F, MacGregor AJ. Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. Clin Exp Rheumatol. 2017;35:1-2.
96. Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul Sultan A. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018;77:1750-6.
97. Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41:19-31.
98. Sattui SE, Xie F, Wan Z, Clinton C, Domsic RT, Curtis JR. Treatment of polymyalgia rheumatica by rheumatology providers: analysis from the American College of Rheumatology RISE registry. Arthritis Care Res. 2024;76:259-64.
99. Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol. 2000;27:1470-6.
100. Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol. 1998;37:189-95.
101. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheumatol. 1997;40:1873-8.
102. Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624-8.
103. Caporali R, Cimmino MA, Ferraccioli G, et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493-500.
104. van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218-23.
105. Marsman DE, Bolhuis TE, den Broeder N, den Broeder AA, van der Maas A. PolyMyalgia rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial. Trials. 2022;23:318.
106. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136-8.
107. Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66:906-9.
108. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638.
109. Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389:1263-72.
110. Tuckwell K, Collinson N, Dimonaco S, et al. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46:657-64.
111. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631-9.
112. Marsman DE, den Broeder N, van den Hoogen FHJ, den Broeder AA, van der Maas A. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol. 2021;3:e758-66.
113. Bolhuis TE, Marsman DE, den Broeder AA, den Broeder N, van der Maas A. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 2023;5:e208-14.
114. Harkins P, Burke E, Swales C, Silman A, Conway R. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. Int J Rheum Dis. 2023;26:31-42.
115. McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398:803-16.
